Cannabis Science, a company specializing in the development of cannabis-based therapies, recently announced the development of two new drugs for pain relief in people with fibromyalgia and diabetic neuropathy with nerve pain.
The two new pharmaceutical analgesics will be marketed as transdermal adhesive patches that deliver a certain dose of medication into the bloodstream by absorption through the patient’s skin.
Routes of transdermal drug administration have the potential to promote healing of an injured area of the body. This method of administration may be superior to other types of drug administration, including oral, topical, intravenous, intramuscular and others, due to additional control over the dose administered to the patient.
The patch provides a more controlled release of the medication, either by using a porous membrane to allow the medication to be gradually absorbed through the skin, or by incorporating thin layers of the medication into the adhesive that melt with body heat of the patient.
Cannabinoids have a wide range of medicinal applications, dating back thousands of years. Currently, several peer-reviewed scientific publications are documenting the underlying biochemical pathways that modulate cannabinoids.
These patches contain high potency cannabinoid extract (CBD), the second major cannabinoid in marijuana after THC (tetrahydrocannabinol). The extract slowly enters the bloodstream and then enters the patient’s central nervous system to act as an analgesic.
CBD has anti-inflammatory and analgesic properties without known psychoactive effects. Research has shown that CBD can be an effective treatment for many types of pain, particularly inflammatory pain. Some studies have also shown that CBD can outperform traditional medication when treating inflammatory pain.
“While we strive to increase our land’s capacity for growth and the facilities to produce our own product to supply our scientists with patented materials to make these formulations, we are also busy investigating more potential needs for medical applications related to Cannabis and developing the methods for delivering these medications, “said Raymond C. Dabney, CEO of Cannabis Science in a press release.
“As more states nationwide [in the US] UU.] Legislate for the legalization of cannabis and cannabis-derived drugs, here at Cannabis Science we are focused on developing formulations and pharmaceutical applications to supply the huge growing demand that is expected in the coming years, “Dabney stated.
It is estimated that fibromyalgia affects 2% -8% of the population. Patients with fibromyalgia experience widespread chronic pain and a greater response to pain under pressure.